Amine Bourbia, MD
Pulmonary Disease · Rome, GANPI 1295141927
Payments from drug & device makers
Across 318 payments — averaging $50.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- GSK$1K
- AstraZeneca$1K
- Boston Scientific$989
- Olympus Corporation Of The Americas$689
- Actelion Pharmaceuticals US, Inc.$505
- plus $3K from 29 others
What the payments were for
- Travel & lodging$2,85118%
- Food & beverage$7,04244%
- Education$6,14738%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 32 | $8,329 |
| GSK | 75 | $1,356 |
| AstraZeneca(2 entities) | 44 | $1,035 |
| Boston Scientific | 11 | $989 |
| Olympus Corporation Of The Americas | 2 | $689 |
| Actelion Pharmaceuticals US, Inc. | 23 | $505 |
| Boehringer Ingelheim | 25 | $473 |
| Mylan Specialty L.p. | 14 | $319 |
| Grifols USA, LLC | 10 | $255 |
| Sanofi | 8 | $225 |
| Amgen | 9 | $184 |
| Insmed, Inc. | 7 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $166 |
| Olympus America Inc. | 1 | $147 |
| United Therapeutics Corporation | 7 | $143 |
| Galvanize Therapeutics, Inc | 1 | $114 |
| ANI Pharmaceuticals, Inc. | 5 | $112 |
| AbbVie(2 entities) | 8 | $108 |
| Harmony Biosciences LLC | 3 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Merck | 3 | $74 |
| Regeneron Healthcare Solutions, Inc. | 2 | $71 |
| Novartis | 3 | $51 |
| Pfizer | 3 | $41 |
| Mallinckrodt Hospital Products Inc. | 1 | $38 |
| Philips North America LLC | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Baxter Healthcare | 1 | $28 |
| Gilead | 1 | $26 |
| Johnson & Johnson | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $18 |
| Inogen, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$6,000
- Da Vinci Surgical System$1,765
- COREDX$298
- GENERAL PULMONARY$276
- Spiration Valve System$147
- BREZTRI$125
- TRELEGY ELLIPTA$124
- ALIYA SYSTEM$114
- NUCALA$102
How this compares
$16,040 in reported general payments places this provider in the 75th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 675 | $554,364 |
| OfevNintedanib Esylate | 37 | $477,906 |
| UptraviSelexipag | 22 | $433,335 |
| OpsumitMacitentan | 28 | $352,650 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 172 | $129,969 |
| NucalaMepolizumab | 23 | $86,144 |
| Spiriva RespimatTiotropium Bromide | 119 | $70,537 |
| Breo ElliptaFluticasone/Vilanterol | 145 | $69,857 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 114 | $57,865 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 89 | $42,185 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 44 | $19,764 |
| Incruse ElliptaUmeclidinium Bromide | 48 | $19,203 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 32 | $19,164 |
| SymbicortBudesonide/Formoterol Fumarate | 68 | $18,817 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 111 | $15,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $505 | $785,98550 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,356 | $771,753980 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $473 | $625,472302 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $1,035 | $168,551284 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Rome
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
- Ngozika OrjiokeEast Point$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.